The reduction in need for medications specific to portal hypertension (ammonia-lowering agents, diuretics, non-selective beta-blockers) indicates that SGLT2 inhibitors may delay or prevent the development of clinically significant portal hypertension. This evidence concerns the gene SLC5A2 and liver disorder.